Skip to content

The value of 68Ga-PSMA PET/CT and 99mTc-PSMA in the diagnosis and prognosis evaluation of prostate cancer

The value of 68Ga-PSMA PET/CT and 99mTc-PSMA in the diagnosis and prognosis evaluation of prostate cancer

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100050381
Enrollment
Unknown
Registered
2021-08-27
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Gold Standard:Pathological results after radical prostatectomy and PSA follow-up.
in&#32
and&#32
of&#32
cancer.

Sponsors

Shanghai East Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Males aged 40-90 years; 2. Patients were diagnosed by prostate biopsy as prostate cancer, and were evaluated as medium or high risk prostate cancer, and will undergo radical prostatectomy; 3. Be willing to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. Unable to tolerate the PET/CT scan, such as those with claustrophobia, unable to lie still, consciousness unclear, vital sign unstable; 2. With renal impairment or allergy to medium contrast; 3. Significant abnormal lab data (AST or ALT more than three times of normal value), and high risk to conduct examination after evaluations of PI; 4. Patients had previous malignancy history; 5. Patients with grade 3-4 neutropenia or thrombocytopenia lasting > 14 days.

Design outcomes

Primary

MeasureTime frame
Gleason Score of prostate cancer;sensitivity;specificity;negative predictive value;positive predictive value;

Countries

China

Contacts

Public ContactZhao Jun

Shanghai East Hospital

261049122@qq.com+86 21 31161718

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026